UB-312 Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson Disease Phase 1 Trial.

Published Date: 03 Aug 2023

Results from the UB-312 phase 1 trial showed that aggregated alpha-synuclein was targeted in the cerebrospinal fluid of Parkinson disease patients, validating the vaccine technology's ability to target aggregated, toxic forms of neurodegenerative proteins.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nuclear missile workers are contracting cancer: They blame the bases

2.

Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants

3.

New analysis helps discern benign from malignant thyroid growths

4.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

5.

Even a few mutated cells can significantly impact how blood cancers develop, study finds


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot